Vanilloid-like agents inhibit aggregation of human platelets

Area of Science:

• Pharmacology
• Biochemistry
• Cardiovascular Research

Background:

• Vanilloid compounds, both plant-derived and endogenous, interact with Transient Receptor Potential Vanilloid-1 (TRPV1) channels.
• The impact of these vanilloids on platelet aggregation remains largely unexplored.
• Understanding these interactions is crucial for developing novel anti-platelet agents.

Purpose of the Study:

• To investigate the effects of various vanilloid-like agents on platelet aggregation in vitro.
• To determine if the observed effects on platelet aggregation are mediated through TRPV1.
• To explore the potential of vanilloids as therapeutic anti-platelet agents.

Main Methods:

• Evaluated plant-derived (capsaicin, dihydrocapsaicin) and endogenous vanilloids (N-oleoyldopamine, N-arachidonoyl-dopamine) on platelet aggregation.
• Utilized adenosine diphosphate (ADP), collagen, and arachidonic acid (AA) as platelet aggregation agonists.
• Assessed platelet viability using lactate dehydrogenase (LDH) release assay to rule out toxicity.

Main Results:

• Capsaicin, N-oleoyldopamine (OLDA), and N-arachidonoyl-dopamine (NADA) inhibited ADP-induced platelet aggregation concentration-dependently.
• OLDA and NADA inhibited collagen-induced aggregation; capsaicin and dihydrocapsaicin (DHC) did not.
• AA-induced aggregation was inhibited by capsaicin, DHC, and NADA, but not OLDA. TRPV1 antagonist did not block capsaicin or OLDA inhibition of ADP-induced aggregation.

Conclusions:

• Endovanilloids (OLDA, NADA) and capsaicin inhibit ADP-induced platelet aggregation via a TRPV1-independent mechanism.
• Differential effects observed for collagen- and AA-induced aggregation suggest distinct pathways.
• These vanilloids show promise as novel anti-platelet agents, warranting further investigation into their mechanisms.